Hepatitis C elimination in Australia: progress and challenges

Marianne Martinello, Behzad Hajarizadeh and Gregory J Dore
Med J Aust 2020; 212 (8): . || doi: 10.5694/mja2.50584
Published online: 4 May 2020

Early empirical evidence provides grounds for optimism about eliminating HCV by 2030

Curative direct‐acting antiviral (DAA) therapy for people with chronic hepatitis C virus (HCV) infections1 has transformed clinical management and spurred ambitious World Health Organization elimination targets for 2030.2 WHO service targets encompass marked improvements in prevention, diagnosis, and treatment; impact targets include a 65% reduction in HCV‐related deaths and an 80% reduction in new HCV infections compared with 2015.2

  • Marianne Martinello
  • Behzad Hajarizadeh
  • Gregory J Dore

  • Kirby Institute, UNSW, Sydney, NSW

Competing interests:

Gregory Dore is an advisory board member and has received honoraria, research grant funding, and travel sponsorship from Merck, Gilead, and Abbvie.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.